

JUNE 2026 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AML3D Limited (ASX: AL3) ("AML3D" or "the Company"), a leader in large scale Wire Additive Manufacturing ("WAM®") technology and 3D metal printing solutions, is pleased to provide the Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2026 (4Q26).

KEY HIGHLIGHTS DURING THE QUARTER

AML3D's focus in 4Q26 was continued delivery against an order book that peaked at **\$29.0 million** during Financial Year 2026 (FY26), made up of \$9 million at the start of FY26 and \$20 million signed during the year, including final commissioning of **ARCEMY systems valued at ~\$6.8 million** during the quarter. Cash receipts during the quarter totalled \$3.5 million, bringing cash receipts for FY26 to **\$10.4 million, up ~20%** on the prior year. \$16.8 million of orders are rolling over to the next financial year.

The key highlights from the quarter include:

- Initial **~\$4.1 million ARCEMY® systems operational** at Newport News Shipbuilding, part of the largest US military shipbuilder.¹
- U.S. Navy Rear Admiral David Goggins (Ret.), and former **AUKUS Special Assistant made US Board advisor**.²
- 1st portable, **~\$1.1 million ARCEMY® system operational** at the US Navy's Additive Manufacturing Centre of Excellence in Danville, Virginia.³
- **~\$1.6 million ARCEMY® system operational** at US Defence, Aerospace and Energy supplier FasTech.⁴

GROWTH STRATEGY

US scale up

AML3D's order book peaked at a record \$29.0 million during FY26. This strong performance was driven, in the main, by the continuing success of the US Scale Up strategy, which also underpins the global sales pipeline, estimated to be \$78 million on 30 June 2026. To ensure AML3D has the capacity to meet the accelerating growth in the US, the \$12 million investment program to double the additive manufacturing (**AM**) capacity at AML3D's Technology Centre in Stow, Ohio (**Stow**) continued during 4Q26.

¹ AML3D Ltd, [First ARCEMY Operation at Largest US Military Shipbuilder](#), 19 June 2026

² AML3D Ltd, [Retired US Navy Rear Admiral Joins as US Board Advisor](#), 16 June 2026

³ AML3D Ltd, [First Portable Arcemy System Online at US Navy COE](#), 06 May 2026

⁴ AML3D Ltd, [ARCEMY X OPERATIONAL AT US DEFENCE SUPPLIER FASTECH](#), 01 April 2026



The expansion of Stow also positions AML3D to take advantage of the continuing strong demand signals across the US Navy Maritime Industrial Base (**MIB**). The MIB includes submarines, aircraft carriers, surface ships, and munitions.

These demand signals continue to convert to orders. An initial \$4.5 million order for two ARCEMY® X systems was placed by Newport News Shipbuilding (**NNS**), a division of Huntington Ingalls Industries, the largest military shipbuilder in the US in 2Q26⁵. This was followed by the largest single ARCEMY® order to date, a \$9.9 million order, also from NNS, for four more ARCEMY® X systems in 3Q26⁶. Final commissioning of the first two systems in the NNS fleet of six ARCEMY®s was completed by AML3D in the current quarter with the remaining 4 systems tracking for on time deliver in early 2027.

In the current quarter, AML3D finalised installation of a first portable ARCEMY® system⁷ for use by Austal USA, which brings their fleet to three systems. Austal USA is a prime supplier to the US Navy and is responsible for the operation of the US Navy's additive manufacturing Centre of Excellence in Danville, Virginia. The portable ARCEMY® system is pre-mounted in a shipping container to allow for easy and rapid redeployment or relocation as needed.

A \$2.6 million order for five high demand, non-safety critical replacement components for the US Navy submarine fleet⁸ commenced in the current quarter. This component order is expected to run for 10 months and supply complex components that are no longer available from the original manufacturer. This second order for non-safety critical replacement components, which are no longer in production, demonstrates AML3D's continuing role in solving US Navy supply chain issues and meeting increasing component demand. AML3D is also continuing several programs to produce material qualification prints for additional Defence applications and the wider commercial industrial manufacturing sectors in the US.

US Advocacy

During the quarter, AML3D accelerated the next phase of its successful US advocacy program with the appointment of US Navy Rear Admiral David Goggins, recently retired, as an advisor to AML3D's US Board. Rear Admiral Goggins led the design, construction, and sustainment of nuclear-powered submarines for the US Navy over the past 34 years and was Special Assistant for the trilateral Australia-United Kingdom-United States (**AUKUS**) defence partnership. Rear Admiral Goggins will join forces with Larissa Smith⁹, who was recently the Director of Additive Manufacturing for the US Navy and became an advisor to AML3D's US Board in 3Q26.

This new phase of advocacy will build greater awareness, at the operational level, within the US Navy MIB supply chain of AML3D's technology to accelerate adoption of ARCEMY® additive manufacturing. David and Larisa are using their extensive network of contacts to deepen relationships with Prime US Navy suppliers, such as HII and Austal USA. They will build on the work of Bondi Partners that created strong AML3D brand awareness with key opinion leaders (**KOLs**) and decision makers in the US Defence, Government and Manufacturing sectors. This work was critical to the adoption of AML3D's technology for the US NAVY Submarine program and wider MIB.

UK & Europe

AML3D continued to build out its UK and European sales pipeline during the quarter. The company had already won a \$1.2 million material feasibility and test block program with UK Defence supplier BAE Systems¹⁰ alongside component manufacturing for a UK defence prime supplier. AML3D's ongoing success in the USA started with component and materials qualification contracts in support of the US Navy's submarine industrial base.

⁵ AML3D Ltd, [\\$4.5M Arcemy Order from the Largest Shipbuilder in the USA](#), 20 October 2025

⁶ AML3D Ltd, [\\$9.9M ARCEMY X ORDER FROM US MILITARY SHIPBUILDER](#), 17 March 2026

⁷ AML3D Ltd, [AML3D Receives \\$1.2M Portable Arcemy System Order](#), 21 July 2025.

⁸ AML3D Ltd, [AML3D RECEIVES AU\\$2.6 MILLION PARTS ORDER FOR US NAVY](#), 26 March 2025.

⁹ AML3D Ltd, [Quarterly Activities/Appendix 4C Cash Flow Report](#), 27 April 2026

¹⁰ AML3D Ltd, [AML3D expands into UK Defence market with alloy test contract](#), 15 April 2025.



The evolution of the UK and European sales pipeline that took place during the quarter is expected to lead to an initial European ARCEMY contract in the short to medium term. Current negotiations indicate an initial European ARCEMY Systems is likely to be installed in the UK. AML3D is also leveraging its US 'Scale up' playbook to optimise UK and European growth. The company's ability to rapidly penetrate the US defence market is being driven by the establishment of the US Technology centre in Stow Ohio. AML3D has already set aside \$5 million of capital for a European Technology Centre¹¹ to help accelerate the company's expansion into key European defence markets. A first ARCEMY contract with a UK Defence supplier will likely be the trigger to establish the European technology centre in the UK.

Australia

AML3D's Australian manufacturing footprint aligns with the key AUKUS defence precincts in Adelaide, South Australia and Perth in Western Australia. AML3D's plans to leverage its existing relationships with US and UK AUKUS suppliers and the appointment, as Board advisor, of former AUKUS specialist, Rear Admiral David Goggins, to secure additional Royal Australian Navy contracts over time. AML3D is already recognised by Austrade as one of the largest exporters under AUKUS¹².

AML3D's Australian Technology Centre at North Plympton in Adelaide (**North Plympton**) is already providing additional capacity to support US and UK Defence manufacturing. North Plympton is running the material feasibility and test block program for BAE Systems UK. AML3D has demonstrated the ability to expand and flex its global manufacturing base to effectively serve geographically diverse markets. This flexibility is allowing AML3D to initiate exploratory discussions to support additional globally significant industrial manufacturing markets in the ASIA Pacific region from Australia.

North Plympton also acts as AML3D's innovation hub. The \$2.24 million ARCEMY® Increase Deposition Rates (**AIDR**) project to accelerate ARCEMY® production¹³ continued at Adelaide during the quarter. This program will keep AML3D's ARCEMY technology at the leading edge of large scale, metal additive manufacturing. The AIDR project is expected to drive additional ARCEMY® system sales and contract manufacturing orders over the medium to longer term.

FINANCIAL UPDATE

AML3D had cash receipts of \$3.5 million in the June 2026 quarter, compared to \$2.2 million in the March 2026 quarter, bringing total cash receipts for the FY2026 financial year to \$10.4 million.

AML3D invested \$1.5 million as a first tranche of the planned, and fully funded, \$12 million investment to double the capacity of the AML3D's US operations. In addition, the \$0.46 million investment in the AIDR R&D project during the quarter brings the cumulative investment in the program to date to \$1.8 million, out of a total project budget of \$2.24 million.

AML3D's delivery against its strong order book resulted in product manufacturing and operating costs of \$1.5 million for the quarter, bringing full financial year operating costs to \$5.2 million.

The company's cash position remains extremely strong at \$26.7 million, on 30 June 2026, providing ample headroom to continue the planned \$12 million expansion of AML3D's US operations and Stow facility and \$5 million investment to establish a European Technology Centre.

OUTLOOK

AML3D's short term growth engine remains US Defence and industrial manufacturing. AML3D has initiated a \$12 million investment to double US manufacturing capacity to ensure the company maximised this US opportunity. In addition, initiating the next phase of AML3D's US advocacy program is expected to unlock multiple additional ARCEMY system and component orders.

¹¹ML3D Ltd, [AML3D to Double US Manufacturing with A\\$30M Capital Raise](#), 6 January 2025

¹²AML3D Ltd, [AML3D Supports AUKUS Supply Chain](#), 6 January 2025.

¹³AML3D Ltd, [AML3D Wins SA Government Grant \\$2.24M Technology Investment](#), 04 June 2024.



The strong early-stage demand signals from the UK and Europe are like those that preceded AML3D's successful entry into the US market and are expected to underpin medium term growth. This will be supported by AML3D's investment to establish a European Technology hub.

AML3D's Australian operations provide manufacturing flexibility to ensure the Company's global growth ambitions will be achieved, while also positioning the company to provide advanced manufacturing services to support Australia's AUKUS commitments. Australia is AML3D's R&D engine that maintains the company's technology leadership, which is a key driver of future sales and revenue growth.

AML3D has also initiated early-stage discussions to leverage its Australian operations and success in deploying ARCEMY technology into globally significant markets to access new, large scale industrial manufacturing markets in the Asia Pacific region. This will underpin longer term growth.

AML3D's is continuing to work through the record \$20 million of orders received in FY26. The demand that underpinned the FY26 record order book continues to grow and AML3D's total sales pipeline has expanded to an estimated \$78 million.

The combination of clearly defined short, medium and long-term growth strategies; a record of \$20 million of orders in FY26, with \$16.8million of orders rolling over to the next financial year and a significantly expanded sales pipeline gives AML3D a great deal of confidence that FY27 will deliver another record revenue performance and AML3D will deliver increased shareholder value over time.

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact:

Sean Ebert
Chief Executive Officer

AML3D Limited
T: +61 429 550 593
E: investor@aml3d.com

Hamish McEwin
Chief Financial Officer

AML3D Limited
T: +61 429 550 593
E: investor@aml3d.com

About AML3D Limited

AML3D Limited, a publicly listed technology company founded in 2014, is disrupting metal part supply chains using the Company's patented Wire Additive Manufacturing (WAM®) process. WAM® combines state-of-the-art welding science, robotics automation, materials engineering and proprietary software to lead metal additive manufacturing globally. AML3D is the OEM of the ARCEMY® industrial metal 3D printing systems. ARCEMY® uses WAM® to provide advanced, automated, on-demand, point-of-need 3D manufacturing solutions that are more efficient, cost-effective and have better ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY® is IIoT and Industry 4.0 enabled to allow manufacturers across Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas to become globally competitive. AML3D also provides metal 3D printing design engineering services, software licencing, technical support, consumable sales and contract manufacturing services.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AML3D Limited

ABN

55 602 857 983

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	3,497	10,419
1.2 Payments for		
(a) research and development	(376)	(1,392)
(b) product manufacturing and operating costs	(1,417)	(5,120)
(c) advertising and marketing	(54)	(308)
(d) leased assets	-	-
(e) staff costs	(1,774)	(6,523)
(f) administration and corporate costs	(716)	(2,975)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	272	1,045
1.5 Interest and other costs of finance paid	(35)	(153)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	352
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(603)	(4,655)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(392)	(1,788)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	13
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	277*
2.6	Net cash from / (used in) investing activities	(392)	(1,498)

* Grant funding received used for capital acquisitions

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	1,232	2,711
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(56)	(223)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	1,176	2,488

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	26,454	30,398
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(603)	(4,655)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(392)	(1,498)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,176	2,488
4.5	Effect of movement in exchange rates on cash held	35	(63)
4.6	Cash and cash equivalents at end of period	26,670	26,670

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	6,670	6,454
5.2	Call deposits	20,000	20,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	26,670	26,454

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
N/A		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(603)
8.2 Cash and cash equivalents at quarter end (item 4.6)	26,670
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	26,670
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	44
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2026

Authorised by: the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.